Transcriptomics and metabolomics analyses indicate that SRL primarily modulates the adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPAR) signaling pathways by regulating genes such as Scd, Fads2, Cpt1a, Lipe, Pfkfb3, and Hmgcs2. Thereby influencing biomarkers such as S-Adenosylmethioninamine (SAM), 16-hydroxyhexadecanoic acid, and proline, mitigating metabolic disorders in pathways such as arginine and proline metabolism, vitamin B6 metabolism, fatty acid degradation, and arachidonic acid metabolism. Here, FADS2 is linked to metabolic disease.